Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042.
Hermida-Prado F, Villaronga MÁ, Granda-Díaz R, Del-Río-Ibisate N, Santos L, Hermosilla MA, Oro P, Allonca E, Agorreta J, Garmendia I, Tornín J, Perez-Escuredo J, Fuente R, Montuenga LM, Morís F, Rodrigo JP, Rodríguez R, García-Pedrero JM. Hermida-Prado F, et al. Among authors: moris f. J Clin Med. 2019 Aug 2;8(8):1157. doi: 10.3390/jcm8081157. J Clin Med. 2019. PMID: 31382448 Free PMC article.
Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
Puente-Moncada N, Costales P, Antolín I, Núñez LE, Oro P, Hermosilla MA, Pérez-Escuredo J, Ríos-Lombardía N, Sanchez-Sanchez AM, Luño E, Rodríguez C, Martín V, Morís F. Puente-Moncada N, et al. Among authors: moris f. Mol Cancer Ther. 2018 Mar;17(3):614-624. doi: 10.1158/1535-7163.MCT-17-0530. Epub 2018 Jan 16. Mol Cancer Ther. 2018. PMID: 29339551
Factors Secreted by Cancer-Associated Fibroblasts that Sustain Cancer Stem Properties in Head and Neck Squamous Carcinoma Cells as Potential Therapeutic Targets.
Álvarez-Teijeiro S, García-Inclán C, Villaronga MÁ, Casado P, Hermida-Prado F, Granda-Díaz R, Rodrigo JP, Calvo F, Del-Río-Ibisate N, Gandarillas A, Morís F, Hermsen M, Cutillas P, García-Pedrero JM. Álvarez-Teijeiro S, et al. Among authors: moris f. Cancers (Basel). 2018 Sep 17;10(9):334. doi: 10.3390/cancers10090334. Cancers (Basel). 2018. PMID: 30227608 Free PMC article.
The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas.
Estupiñan O, Santos L, Rodriguez A, Fernandez-Nevado L, Costales P, Perez-Escuredo J, Hermosilla MA, Oro P, Rey V, Tornin J, Allonca E, Fernandez-Garcia MT, Alvarez-Fernandez C, Braña A, Astudillo A, Menendez ST, Moris F, Rodriguez R. Estupiñan O, et al. Among authors: moris f. Int J Cancer. 2019 Jul 1;145(1):254-266. doi: 10.1002/ijc.32081. Epub 2019 Jan 14. Int J Cancer. 2019. PMID: 30575954 Free article.
The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S, Sordo-Bahamonde C, Bretones G, Payer ÁR, González-Rodríguez AP, González-García E, Pérez-Escuredo J, Villa-Álvarez M, Núñez LE, Morís F, Gonzalez S, López-Soto A. Lorenzo-Herrero S, et al. Among authors: moris f. Front Immunol. 2019 Oct 18;10:2455. doi: 10.3389/fimmu.2019.02455. eCollection 2019. Front Immunol. 2019. PMID: 31681329 Free PMC article.
Mithramycin delivery systems to develop effective therapies in sarcomas.
Estupiñán Ó, Niza E, Bravo I, Rey V, Tornín J, Gallego B, Clemente-Casares P, Moris F, Ocaña A, Blanco-Lorenzo V, Rodríguez-Santamaría M, Vallina-Álvarez A, González MV, Rodríguez A, Hermida-Merino D, Alonso-Moreno C, Rodríguez R. Estupiñán Ó, et al. Among authors: moris f. J Nanobiotechnology. 2021 Sep 6;19(1):267. doi: 10.1186/s12951-021-01008-x. J Nanobiotechnology. 2021. PMID: 34488783 Free PMC article.
55 results